Abstract
Fluorouracil (5-fluorouracil, 5-FU) is a pyrimidine analogue that was originally known for its widespread use as an anticancer drug. The ability of 5-FU to reduce fibroblastic proliferation and subsequent scarring has made it an important adjunct in ocular and periorbital surgeries. It is used in primary glaucoma filtering surgeries and in reviving failing filtering blebs, in dacryocystorhinostomy, pterygium surgery, and in vitreoretinal surgery to prevent proliferative vitreoretinopathy. In addition, 5-FU is also gaining recognition in the treatment and surgical management of ocular surface malignancies like ocular surface squamous neoplasia; however, the specific action of the drug on highly proliferating cells limits its use in primary acquired melanosis of the conjunctiva. When applied topically, this drug has a low rate of sight-threatening adverse effects, is inexpensive, and is easy to administer, making it an important tool in enhancing the success rate in ophthalmic surgery and in reducing the recurrence of ocular surface neoplasia.
Similar content being viewed by others
Notes
The use of trade names is for product identification purposes only and does not imply endorsement.
References
Dushinski R, Pleven E, Heidelberger C. The synthesis of 5 fluoro pyrimidines. J Am Chem Soc 1957; 79: 4559–60
Milano G, Ferrero J-M, Francois E. Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation. Br J Cancer 2004; 91: 613–7
Malet-Martino M, Jolimaitre P, Martino R. The prodrugs of 5-fluorouracil. Curr Med Chem-Anticancer Agents 2002; 2: 267–310
Kubota T. 5-Fluorouracil and dihydropyrimidine dehydrogenase. Int J Clin Oncol. 2003; 8: 127–31
Chabner BA, Allegra CJ, Curt GA, et al. Antineoplastic agents: pyrimidine analogs. In: Hardman JG, Limbird LE, Molinoff PB, et al., editors. Goodman and Gilman’s The pharmacological basis of therapeutics, 9th ed. New York: McGraw Hill,1996: 1247–51
Heimer R, Sartorelli AC. Reductions in gamma globulin mRNA levels restricted to the cytoplasm of 5-flurouridine treated K-562 human erythroleukemia cells. Cancer Commun 1990; 2: 45–3
Gordon SR, Climie M, Hitt AL. 5-Fluorouracil interferes with actin organization, stress fibre formation and cell migration in corneal endothelial cells during wound repair along the natural basement membrane. Cell Motil Cytoskeleton 2005; 62: 244–58
Khaw PT, Ward S, Porter A, et al. The long term effects of 5-fluorouracil and sodium butyrate on human tenon’s fibroblasts. Invest Ophthalmol Vis Sci 1992; 33: 2043–52
Ashktorab H, Dawkins FW. Mohamed R, et al. Apoptosis induced by aspirin and 5-fluorouracil in human colonic adenocarcinoma cells. Dig Dis Sci 2005; 50: 1025–32
Ophir A. Effects of 5-fluorouracil on proliferating fibroblasts in vivo. Exp Eye Res 1991; 53: 799–803
Khaw FT, Sherwood MB, Mackay SLD. Five minute treatments with fluorouracil, floxuridine and mitomycin have long term effects on human Tenon’s capsule fibroblasts. Arch Ophthalmol 1992; 110: 1150–4
Occleston NL, Alexander RA, Mazure A, et al. Effect of single exposures to antiproliferative agents on ocular fibroblast mediated collagen contraction. Invest Ophthalmol Vis Sci 1994; 35: 3681–90
Smith S, D’Amore PA, Dreyer EB. Comparative toxicity of mitomycin C and 5-fluorouracil in vitro. Am J Ophthalmol 1993; 116: 673–83
Blumenkranz MS, Claflin A, Hajek AS. Selection of therapeutic agents for intraocular proliferative disease: cell culture evaluation. Arch Ophthalmol 1984; 102: 598–604
Rootman J, Tisdall J, Gadauskas G, et al. Intraocular penetration of subconjunctivally administered 14C-fluorouracil in rabbits. Arch Ophthalmol 1979; 97: 2375–8
Fantes FE, Heuer DK, Parrish RK III, et al. Topical fluorouracil: pharmacokinetics in normal rabbit eyes. Arch Ophthalmol 1985; 103: 953–5
Simmons ST, Sherwood MB, Nichols DA, et al. Pharmacokinetics of a 5-fluorouracil liposomal delivery system. Br J Ophthalmol 1988; 72: 688–91
Merriman MB, Mora JS, Beaumont BW, et al. Effects of varying 5-fluorouracil exposure duration on Tenon’s capsule fibroblasts. Clin Exp Ophthalmol 2001; 29: 248–52
Jams G, Blumenkranz M, Hernandez E, et al. Clearance of intravitreal fluorouracil: normal and aphakic vitrectomized eyes. Ophthalmology 1985; 92: 91–6
Blumenkranz MS, Ophir A, Claflin AJ, et al. Fluorouracil for treatment of massive pre retinal proliferation. Am J Ophthalmol 1982; 94: 458–67
Lama PJ, Fechtner RD. Antifibrotics and wound healing in glaucoma surgery. Surv Ophthalmol 2003; 48: 314–46
Costa PV, Spaeth GL, Eiferman RA, et al. Wound healing modulation in glaucoma filtering surgery. Ophthalmic surgery 1993; 24: 152–70
Peng TK, Migdal CS. Current techniques in wound healing modulation in glaucoma surgery. Curr Opin Ophthalmol 1996; 7: 24–33
Weinreb RN. Adjusting the dose of 5-fluorouracil after filtering surgery to minimize side effects. Ophthalmology 1987; 94: 564–70
Heuer DK, Parrish RK, Gressel MG. 5-Fluorouracil and glaucoma filtering surgery II: a pilot study. Ophthalmology 1984; 94: 1071–8
Spaeth GI, Mutlukan E. The use of antimetabolites with trabeculectomy: a critical appraisal. J Glaucoma 2001; 10: 145–51
Heuer DK, Parrish RK, Gressel MG, et al. 5-Fluorouracil and glaucoma filtering surgery III: intermediate follow up of a pilot study. Ophthalmology 1986; 93: 1537–46
Ruderman J, Welch D, Smith M, et al. A randomized trial of 5 fluorouracil and filtration surgery. Am J Ophthalmol 1987; 104: 218–24
Araie M, Shoji N, Shirato S, et al. Postoperative subconjunctival 5-fluorouracil injections and success probability of trabeculectomy in Japanese: results of 5-year follow-up. Jpn J Ophthalmol 1992; 36: 158–68
Ophir A, Ticho U. A randomized study of trabeculectomy and subconjunctival administration of fluorouracil in primary glaucomas. Arch Ophthalmol 1992; 110: 1072–5
Goldenfeld M, Krupin T, Ruderman JM, et al. 5-Fluorouracil in initial trabeculectomy: a prospective, randomized, multicenter study. Ophthalmology 1994; 101: 1024–9
The Fluorouracil Filtering Surgery Study Group. Five year follow up of the fluorouracil surgery study. Am J Ophthalmol 1996; 121: 349–66
Chaudry IA, Pasha MA, O’Connor DJ, et al. Randomized, controlled study of low-dose 5-fluorouracil in primary trabeculectomy. Am J Ophthalmol 2000; 130: 700–3
Rothman RF, Liebmann JM, Ritch R. Low-dose 5-fluorouracil trabeculectomy as initial surgery in uncomplicated glaucoma: long-term follow up. Ophthalmology 2000; 107: 1184–90
Akarsu C, Onol M, Hasareisoglu B. Post operative 5-fluorouracil versus intraoperative mitomycin C in high-risk glaucoma filtering surgery: extended follow up. Clin Experiment Ophthalmol 2003; 31: 199–205
Anand N, Sahni K, Menage MJ. Modification of trabeculectomy with single-dose intraoperative 5-fluorouracil application. Acta Ophthalmol Scand 1998; 76: 83–9
Mielke C, Dawda VK, Anand N. Intraoperative 5-fluorouracil application during primary trabeculectomy in Nigeria: a comparative study. Eye 2003; 17: 829–34
Bell RW, Habib NE, O’Brien C. Long-term results and complications after trabeculectomy with a single per-operative application of 5-fluorouracil. Eye 1997; 11: 663–71
Mora JS, Nguyen N, Iwach AG, et al. Trabeculectomy with intraoperative sponge 5-fluorouracil. Ophthalmology 1996; 103: 963–70
Sidoti PA, Choi JC, Morinelli EN, et al. Trabeculectomy with intraoperative 5-fluorouracil. Ophthalmic Surg Lasers 1998; 29: 552–61
Wudunn D, Cantor LB, Palanca-Capistrano AM, et al. A prospective randomized trial comparing intraoperative 5-fluorouracil vs mitomycin C in primary trabeculectomy. Am J Ophthalmol 2002; 134: 521–7
Singh K, Mehta K, Shaik NM, et al. Trabeculectomy with intraoperative mitomycin C versus 5-fluorouracil: prospective randomized clinical trial. Ophthalmology 2000; 107: 2305–9
Suzuki R, Dickens CJ, Iwach AG, et al. Long-term follow-up of initially successful trabeculectomy with 5-fluorouracil injections. Ophthalmology 2002; 109: 1921–4
Wolner B, Liebmann JM, Sassani JW, et al. Late bleb-related endophthalmitis after trabeculectomy with adjunctive 5-fluorouracil. Ophthalmology 1991; 98: 1053–60
Siriwardena D, Kotecha A, Minassian D, et al. Anterior chamber flare after trabeculectomy and after phacoemulsification. Br J Ophthalmol 2000; 84: 1056–7
Lochhead J, Casson RJ, Salmon JF. Long term effect on intraocular pressure of phacotrabeculectomy compared to trabeculectomy. Br J Ophthalmol 2003; 87: 850–2
Fraser S, Phelan PS. Cataract surgery and IOP. Br J Ophthalmol 2005; 89: 1228
Hennis HL, Stewart WB. The use of 5 fluorouracil in patients following combined trabeculectomy and cataract extraction. Ophthalmic Surg 1991; 22: 451–4
O’Grady JM, Juzych MS, Shin DH, et al. Trabeculectomy, phacoemulsification, and posterior chamber lens implantation with and without 5-fluorouracil. Am J Ophthalmol 1993; 116: 594–595 99
Gandolfi SA, Vecchi M. 5-Fluorouracil in combined trabeculectomy and clear-cornea phacoemulsification with posterior chamber intraocular lens implantation: a one-year randomized, controlled clinical trial. Ophthalmology 1997; 104: 181–6
Ren J, Shin DH, O’Grady JM, et al. Long-term outcome of primary glaucoma triple procedure with adjunctive 5-fluorouracil. Graefes Arch Clin Exp Ophthalmol 1998; 236: 501–6
Budenz DL, Pyfer M, Singh K, et al. Comparison of phacotrabeculectomy with 5-fluorouracil, mitomycin-C, and without antifibrotic agents. Ophthalmic Surg Lasers 1999; 30: 367–74
Donoso R, Rodriguez A. Combined versus sequential phacotrabeculectomy with intraoperative 5-fluorouracil. J Cataract Refract Surg 2000; 26: 71–4
Singh RP, Goldberg I, Mohsin M. The efficacy and safety of intraoperative and/or postoperative 5-fluorouracil in trabeculectomy and phacotrabeculectomy. Clin Experiment Ophthalmol 2001; 29: 296–302
Zalish M, Leiba H, Oliver M. Subconjunctival injection of 5-fluorouracil following trabeculectomy for congenital and infantile glaucoma. Ophthalmic Surg 1992; 23: 203–5
Snir M, Luskey M, Shalev B, et al. Mitomycin C and 5-fluorouracil antimetabolite therapy for pediatric glaucoma filtration surgery. Ophthalmic Surg Lasers 2000; 31: 31–7
Cantor L, Burgoyne J, Sanders S, et al. The effect of mitomycin C on molteno implant surgery. J Glaucoma 1998; 7: 240–6
Trible JR, Brown DB. Occlusive ligature and standardized fenestration of a Baerveldt tube with and without antimetabolites for early postoperative intraocular pressure control. Ophthalmology 1998; 105: 2243–50
Jacob JT, Lacour OJ, Burgoyne CF. Slow release of the antimetabolite 5-fluorouracil (5-FU) from modified Baerveldt glaucoma drains to prolong drain function. Biomaterials 2001; 22: 3329–35
Broadway DC, Bloom PA, Bunce C, et al. Needle revision of failing and failed trabeculectomy blebs with adjunctive 5-fluorouracil: survival analysis. Ophthalmology 2004; 111: 665–73
Allen LE, Manuchehri K, Corridan PG. The treatment of encapsulated trabeculectomy blebs in an out-patient setting using a needling technique and subconjunctival 5-fluorouracil injection. Eye 1998; 12: 119–23
Shin DH, Juzych MS, Khatana AK, et al. Needling revision of failed filtering blebs with adjunctive 5-fluorouracil. Ophthalmic Surg 1993; 24: 242–8
Ophir A, Porges Y. Needling with intra bleb 5-fluorouracil for intractable neovascular glaucoma. Ophthalmic Surg Lasers 2000; 31: 38–42
Dion E. The treatment of pterygium. Ophthalmic Surg 1977; 8: 12–30
Lewallen S. A randomized controlled trial of conjunctival autografting for pterygium in the tropics. Ophthalmology 1989; 96: 1612–4
Essex RW, Snibson GR, Daniell M, et al. Amniotic membrane grafting in the surgical management of primary pterygium. Clin Exp Ophthalmol 2004; 32: 501–4
Brenner DJAU, Merriam GR. Postoperative radiation for pterygium: guidelines for optimal treatment. Int J Radiat Oncol Biol Phys 1994; 30: 721–5
Rubinfeld RS, Pfister RR, Stein RM, et al. Serious complications of topical mitomycin-C after pterygium surgery. Ophthalmology 1992; 99: 1647–54
Hsiao CH, Chen JJ, Huang SC, et al. Intrascleral dissemination of infectious scleritis following pterygium excision. Br J Ophthalmol 1998; 82: 29–34
Dougherty PJ, Hardten DR, Lindstrom RL. Corneoscleral melt after pterygium surgery using a single intraoperative application of mitomycin-C. Cornea 1996; 15: 537–40
Maldonado MJ, Cano-Parra J, Navea-Tejerina A, et al. Inefficacy of low dose intraoperative fluorouracil in the treatment of primary pterygium. Arch Ophthalmol 1995; 113: 1356–7
Bekibele CO, Baiyeroju AM, Ajayi BGK. 5-Fluorouracil vs. beta-radiation in the prevention of pterygium recurrence. Int J Clin Pract 2004; 58: 920–3
Pikkel J, Porges Y, Ophir A. Halting pterygium recurrence by postoperative 5 fluorouracil. Cornea 2001; 20: 168–71
Akarsu C, Taner P, Ergin A. 5-Fluorouracil as chemoadjuvant for primary pterygium surgery: preliminary report. Cornea 2003; 22: 522–6
Prabhasawat P, Tesavibul N, Leelapatranura K, et al. Efficacy of subconjunctival 5-fluorouracil and triamcinolone injection in impending recurrent pterygium. Ophthalmology 2006; 113: 1102–9
Toti A. Nuovo metodo conservatore di cura radicale delie suporazioni chroniche del sacco lacrimale. Clin Mod Firenze 1904; 10: 385–9
Iliff CE. A simplified dacryocystorhinostomy. Arch Ophthalmol 1971; 85: 586–91
Pico G. A modified technique of external dacryocystorhinostomy. Am J Ophthalmol 1971; 72: 679–89
Bakri K, Jones NS, Downes R, et al. Intraoperative fluorouracil in endonasal laser dacryocystorhinostomy. Arch Otolaryngol Head Neck Surg 2003; 129: 233–5
Bakri SJ, Carney AS, Downes RN, et al. Endonasal laser assisted dacryocystorhinostomy: a review. Hosp Med 1998; 59: 210–5
Sadiq SA, Ohrlich S, Jones NS, et al. Endonasal laser dacryocystorhinostomy-medium term results. Br J Ophthalmol 1997; 81: 1089–92
Boush GA, Lemke BN, Dortzbach RK. Results of endonasal laser assisted dacryocystorhinostomy. Ophthalmology 1994; 101: 955–9
Tarbet KJ, Custer PL. External dacryocystorhinostomy: surgical success, patient satisfaction, and economic cost. Ophthalmology 1995; 102: 1065–70
Walland MJ, Rose GE. Factors affecting the success rate of open lacrimal surgery. Br J Ophthalmol 1994; 78: 888–91
Yalaz M, Firinciogullari E, Zeren H. Use of mitomycin C and 5-fluorouracil in external dacryocystorhinostomy. Orbit 1999; 18: 239–45
Watts P, Ram AR, Nair R, et al. Comparison of external dacryocystorhinostomy and 5-fluorouracil augmented endonasal laser dacryocystorhinostomy: a retrospective review. Indian J Ophthalmol 2001; 49: 169–72
Machemer R. Proliferative vitreoretinopathy: a personal account of its pathogenesis and treatment. Invest Ophthalmol Vis Sci 1988; 29: 1771–83
The Silicone Study Group. Proliferative vitreoretinopathy. Am J Ophthalmol. 1985; 99: 593–5
Chandler DB, Rozakis G, Dejuan E, et al. The effect of triamcinolone acetonide on a refined experimental model of proliferative vitreoretinopathy. Am J Ophthalmol 1985; 99: 686–90
Khawly JA, Saloupis P, Hatchell DL, et al. Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol 1991; 229: 464–7
Yang CS, Khawly JA, Hainsworth DP, et al. An intravitreal sustained release triamcinolone and 5-flourouracil in the treatment of experimental proliferative vitreoretinopathy. Arch Ophthalmol 1998; 116: 69–77
Kon CH, Accleston NL, Foss A, et al. Effects of single, short term exposures of human retinal pigment epithelial cells to thiotepa and 5-fluorouracil: implications for the treatment of proliferative vitreoretinopathy. Br J Ophthalmol 1998; 82: 554–60
Blumenkranz M, Hernandez E, Ophir A, et al. 5-Fluorouracil: new applications of complicated retinal detachment for an established antimetabolite. Ophthalmology 1984; 91: 122–30
Blankenship GW. Evaluation of a single intravitreal injection of 5-fluorouracil in vitrectomy cases. Graefes Arch Clin Exp Ophthalmol 1989; 227: 565–8
Asaria RH, Kon CH, Bunce C, et al. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized double blind clinical trial. Ophthalmology 2001; 108: 1179–83
Charteris GD, Aylward GW, Wong D, et al. A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy. Ophthalmology 2004; 111: 2240–5
Cardillo JA, Farah ME, Mitre J, et al. An intravitreal biodegradable sustained release naproxen and 5-fluorouracil system for the treatment of experimental post traumatic proliferative vitreoretinopathy. Br J Ophthalmol 2004; 88: 1201–5
Majumdar PA, Epstein RJ. Antimetabolites in ocular surface neoplasia. Curr Opin Ophthalmol 1998; 9: 35–9
Lee GA, Hirst LW. Ocular surface squamous neoplasia. Surv Ophthalmol 1995; 39: 429–50
Basti S, Macsai MS. Ocular surface neoplasia: a review. Cornea 2003; 22: 687–704
de Keizer RJW, de Wolff-Rouendall D, van Delft JL. Topical application of 5-fluorouracil in premalignant lesions of cornea conjunctiva and eyelid. Doc Ophthalmol 1986; 64: 31–42
Yeatts RP, Ford JG, Stanton CA, et al. Topical 5-fluorouracil in treating epithelial neoplasia of the conjunctiva and cornea. Ophthalmology 1995; 102: 1338–44
Midena E, Boccato P, Angeli CD. Conjunctival squamous cell carcinoma treated with topical 5-fluorouracil. Arch Ophthalmol 1997; 115: 1600–1
Midena E, Angeli CD, Valenti M, et al. Treatment of conjunctival squamous cell carcinoma with topical 5-fluorouracil. Br J Ophthalmol 2000; 84: 268–72
Yeatts RP, Engelbrecht NE, Curry CD, et al. 5-Fluorouracil for the treatment of intraepithelial neoplasia of the conjunctiva and cornea. Ophthalmology 2000; 107: 2190–5
Yamamoto N, Ohmura T, Suzuki H, et al. Successful treatment with 5-fluorouracil of conjunctival intraepithelial neoplasia refractive to mitomycin-C. Ophthalmology 2002; 109: 249–52
Lin SM, Ferrucci S. Primary acquired melanosis of the conjunctiva. Optometry 2006; 77: 223–8
Stone DU, Butt AL, Chodosh J. Ocular surface squamous neoplasia: a standard of care survey. Cornea 2005; 24: 297–300
Shapiro MS, Thoft RA, Friend J, et al. 5-Fluorouracil toxicity to the ocular surface epithelium. Invest Ophthalmol Vis Sci 1985; 26: 580–3
Knapp A, Heuer DK, Stern GA, et al. Serious corneal complications of glaucoma filtering surgery with post operative 5-fluorouracil. Am J Ophthalmol 1987; 103: 183–7
Traverso CE, Facino M, Murialdo U, et al. Decrease corneal complications after no reflux, low dose 5 fluorouracil subconjunctival injection following trabeculectomy. Int Ophthalmol 1994; 18: 247–50
Mochizuki K, Jikiihara S, Ando Y, et al. Incidence of delayed onset infection after trabeculectomy with adjunctive mitomycin C or 5-fluorouracil treatment. Br J Ophthalmol 1997; 81: 877–83
Susanna R, Takahashi W, Nicolele M. Late bleb leakage after trabeculectomy with 5-fluorouracil or mitomycin C. Can J Ophthalmol 1996; 31: 296–300
Solomon A, Ticho U, Frucht-Pery J. Late-onset, bleb-associated endophthalmitis following glaucoma filtering surgery with or without antifibrotic agents. J Ocul Pharmacol Ther 1999; 15: 283–93
Song A, Scott IU, Flynn HW, et al. Delayed-onset bleb-associated endophthalmitis: clinical features and visual acuity outcomes. Ophthalmology 2002; 109: 985–91
Ticho U, Ophir A. Late complications after glaucoma filtering surgery with adjunctive 5-fluorouracil. Am J Ophthalmol 1993; 115: 506–10
Wells AP, Cordiero MF, Bunce C, et al. Cystic bleb formation and related complications in limbus-versus fornix-based conjunctival flaps in pediatric and young adult trabeculectomy with mitomycin C. Ophthalmology 2003; 110: 2192–7
Abraham LM, Selva D, Casson RJ, et al. Mitomycin: clinical applications in ophthalmic practice. Drugs 2006; 66: 321–40
Lamping KA, Belkin JK. 5-Fluorouracil and mitomycin C in pseudophakic patients. Ophthalmology 1995; 102: 70–5
Singh K, Egbert PR, Byrd S, et al. Trabeculectomy with intraoperative 5-fluorouracil vs. mitomycin C. Am J Ophthalmol 1997; 123: 48–53
Vijaya L, Mukhesh BN, Shantha B, et al. Comparison of low dose intraoperative mitomycin C vs. 5-fluorouracil in primary glaucoma surgery: a pilot study. Ophthalmic Surg Lasers 2000; 31: 24–30
Smith MF. Doyle JW, Nguyen QH, et al. Results of intraoperative 5-fluorouracil or lower dose mitomycin C on initial trabeculectomy surgery. J Glaucoma 1997; 6: 104–10
Katz GJ, Higginbotham GJ, Lichter PR, et al. Mitomycin C versus 5-fluorouracil in high-risk glaucoma filtering surgery: extended follow-up. Ophthalmology 1995; 102: 1263–9
Membrey WL, Poinooswamy DP, Bunce C, et al. Glaucoma surgery with or without adjunctive antiproliferatives in normal tension glaucoma: intraocular pressure control and complications. Br J Ophthalmol 2000; 84: 586–90
Andreo LK, Uyemura MJ, Enzenaur RW. 5-Fluorouracil reduces scarring after strabismus surgery. J Pediatr Ophthalmol Strabismus 1997; 34: 107–10
Esme A, Yidirim C, Tatlipinar S, et al. Effects of intraoperative sponge mitomycin C and 5-fluorouracil on scar formation following strabismus surgery in rabbits. Strabismus 2004; 12: 141–8
Hwang JM. Chang BL. Combined effect of polytetrafluoroethylene and 5-fluorouracil on delayed adjustable strabismus surgery. J Pediatr Ophthalmol Strabismus 2000; 37: 163–7
Hwang JM. Chang BL. Combined effect of Interceed and 5-fluorouracil on delayed adjustable strabismus surgery. Br J Ophthalmol 1999; 83: 788–91
Ismail MM, Alio JL, Ruiz Moreno JM. Prevention of secondary cataract by antimitotic drugs: experimental study. Ophthalmic Res 1996; 28: 64–9
Fernandez V, Fragoso MA, Billotte C, et al. Efficacy of various drugs in the prevention of posterior capsule opacification: experimental study of rabbit eyes. J Cataract Refract Surg 2004; 30: 2598–605
Acknowledgements
No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Abraham, L.M., Selva, D., Casson, R. et al. The Clinical Applications of Fluorouracil in Ophthalmic Practice. Drugs 67, 237–255 (2007). https://doi.org/10.2165/00003495-200767020-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-200767020-00005